ProstaVive
Prostate-support product guide
View Product
What does “longevity supplement” mean in the MenPS catalog?
Longevity is a broad commercial-positioning category rather than one single supplement mechanism. Products can be marketed around healthy ageing, cellular support, energy metabolism, antioxidant support, mitochondrial function or NAD-related pathways. MenPS treats those as distinct product approaches and does not imply that inclusion proves lifespan extension or disease prevention.
The current six-product snapshot contains several different formula strategies. Some are explicitly NAD-precursor products, while others belong to broader healthy-ageing or cellular-support positioning. That distinction is the main reason this page remains separate from the narrower NAD-support directory.
The current inventory should be grouped by product approach before it is compared
The most useful first split is between NAD-precursor products and broader longevity-positioned formulas. Tru Niagen and Life Extension NAD+ Cell Regenerator are nicotinamide riboside products. Thorne NiaCel 400 is also positioned around nicotinamide riboside/NAD support within a healthy-ageing context. By contrast, a broad longevity page can also include products built around different nutrient or antioxidant strategies when the current product record supports that positioning.
This creates the first information-gain element for the page: longevity is not synonymous with NAD support. NAD-related products are one subset within a larger healthy-ageing market, so a broad longevity page should compare mechanisms and formula families instead of repeating the NAD directory.
NAD support is one subcategory inside longevity
Tru Niagen currently provides 300 mg of Niagen nicotinamide riboside chloride per vegetarian capsule. Life Extension NAD+ Cell Regenerator currently provides 300 mg of NIAGEN nicotinamide riboside chloride per capsule. Thorne continues to list NiaCel 400 in its healthy-ageing range, although exact current amount representation should be rechecked immediately before any material publishing update because current surfaced Thorne pages have shown closely related 400 mg and 415 mg presentations.
These products belong naturally inside a longevity discovery map, but their detailed precursor type, dose and serving-format comparison belongs on the NAD-support page.
What should users compare across broad longevity products?
- Primary product approach: NAD precursor, antioxidant, mitochondrial-support, nutrient blend or another clearly disclosed mechanism.
- Ingredient identity and form: the exact compound matters more than broad “healthy ageing” front-label wording.
- Disclosed amount per serving: use the current label where available and preserve unknown fields rather than infer them.
- Serving format: capsule, powder or combination formula.
- Formula complexity: single-ingredient versus multi-ingredient product.
- Verification date: formulations and commercial availability change over time.
What the current category structure reveals
The current MenPS architecture contains enough NAD-focused inventory to justify a separate NAD page. That means the longevity page should function as a mechanism map rather than a duplicate list. A user starting with “longevity supplements” may not yet know whether they want an NAD precursor, antioxidant strategy or a broader healthy-ageing formula.
The second information-gain element is therefore architectural: the broad page should help users narrow the market by mechanism, while the NAD page should compare NAD-related products at ingredient and dose level.
It also improves AI and search retrieval because the page can answer a distinct question: the broad market is a collection of different product strategies, while the NAD page is a focused comparison of one of those strategies.
A useful sequence is: identify the principal active strategy, confirm the exact ingredient form, record the full serving, note whether the formula is single-ingredient or combined, check whether the label discloses individual amounts, and then move to independent evidence for the underlying ingredients. This prevents broad “longevity” language from hiding large differences between products.
For a broad longevity page, the first buying question should be which product approach is actually being compared. A single-ingredient NAD precursor should not be scored against a multi-nutrient healthy-ageing blend as though they are substitutes. Instead, MenPS should first classify the mechanism or ingredient family, then compare the fields that matter inside that subgroup.
A practical decision framework for broad longevity products
Healthy-ageing positioning is not proof of longevity outcomes
Manufacturer product pages can verify current product identity, formula, serving size and commercial positioning. They cannot by themselves establish that a finished supplement extends lifespan, prevents ageing-related disease or produces a specific clinical outcome. MenPS records the catalog facts and keeps independent evidence interpretation separate.
Verification and freshness
The NAD-related products used in this differentiated snapshot were rechecked against current official manufacturer sources during the September audit. Any broader longevity inventory that is not freshly verified should remain excluded from new derived comparisons until its exact current product page or label is confirmed.
Useful follow-up questions
Are longevity supplements the same as NAD supplements?
No. NAD supplements are one narrower product class inside the broader longevity and healthy-ageing market.
Does a “healthy ageing” label prove a longevity benefit?
No. It describes commercial positioning. Independent evidence requires a separate source base.
Why keep a broad longevity page if there is an NAD page?
The broad page helps users compare different product approaches before choosing a narrower mechanism-specific category.
Primary product sources used for this snapshot
Product identity, ingredient form, serving information and current commercial positioning were checked against official manufacturer pages. These sources support catalog facts, not independent efficacy conclusions.